Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (ERCANUT)

Assessment of Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (CKD) After the Implementation of a Nutritional Education Plan and Individualized Dietary Intervention

This study evaluates the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.

Study Overview

Detailed Description

Randomized study including two parallel groups: patients from the advanced chronic kidney disease (CKD) consulting room of the Malaga University Regional Hospital and controls. The main objective is to assess the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.

Both groups will be composed of 54 participants. The control group will be provided general dietary and lifestyle recommendations (standard procedure in the nephrology consulting room), whereas the intervention group will receive treatment and individualized dietary follow-up using coaching techniques, supported by information and communication technologies, and will participate in a nutritional education program composed of four on-line sessions.

Two visits (basal and three months after) will be scheduled during the study to obtain and analyse the data. Moreover, in these visits researchers will collect a blood sample in order to perform an assessment of the metabolism, inflammation, and oxidation, and a stool sample in order to evaluate the gut microbiota.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Málaga, Spain, 29009
        • Hospital Regional Universitario de Malaga

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Patients >18 years old with advanced CKD (GFR <30ml/min) starting follow-up in the advanced CKD consulting room of the Malaga University Regional Hospital and who clearly understand the study and give their informed consent.

Exclusion Criteria:

  • Patients presenting any of these conditions:

    • Active cancer
    • Being already participants of another study that may affect the results
    • Pregnancy or possible pregnancy
    • Informed consent refusal
    • Hospital admission during one month previous to the study
    • Severe mental disorders (SMD), prolonged mental disorders involving a high level of disability and social dysfunction, which requires attendance by the mental health and social care network
    • Alcohol or any other substance abuse that, in the researcher's opinion, may interfere with the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental: nutritional education program
Specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
No Intervention: Control Group
Dietary and general lifestyle recommendations

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess the clinical response after the quality of life intervention
Time Frame: From baseline to week 12
Kidney Disease and Quality of Life test (KDQOL-36). The generic component of the KDQOL-36 (items 1-12) is the SF-12, which allows obtaining 2 general scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The specific component of the KDQOL-36 (items 13-36), allows obtaining the scores of the specific subscales for the disease.
From baseline to week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in weight
Time Frame: From baseline to week 12
Weight in kg
From baseline to week 12
BMI (body mass index) changes
Time Frame: From baseline to week 12
Measured by body composition analysis
From baseline to week 12
Change in cholesterol concentration
Time Frame: From baseline to week 12
Serum cholesterol in mg/dl
From baseline to week 12
Change in HDL concentration
Time Frame: From baseline to week 12
Serum HDL in mg/dl
From baseline to week 12
Change in LDL concentration
Time Frame: From baseline to week 12
Serum LDL in mg/dl
From baseline to week 12
Characterize exercise participant behavior
Time Frame: From baseline to week 12
International Physical Activity Questionnaire (IPAQ). The IPAQ consists of 7 questions about the frequency, duration and intensity of activity (moderate and intense) carried out in the last seven days, as well as walking and sitting time in a work day. It evaluates three characteristics of physics (PA): intensity (mild, moderate or vigorous), frequency (days per week) and duration (time per day). Weekly activity is recorded in Mets (Metabolic Equivalent of Task or Metabolic Index Units) per minute and week.
From baseline to week 12
Assess the clinical response after intervention in the management of CKD
Time Frame: From baseline to week 12

Self-Efficacy for Managing Chronic Disease test. The Self-Efficacy Scale for the Management of Chronic Diseases (SEMCD) is made up of 6 items on an analog scale, ranging from 1 (not at all sure) to 10 (totally safe).

The Spanish version (SEMCD-S) consists of 4 items. A higher number means greater self-efficacy. The scale score is the mean of the items.

From baseline to week 12
Assess the clinical response after the intervention in knowledge about the disease
Time Frame: From baseline to week 12
Kidney Disease Knowledge Survey test. The Kidney Disease Knowledge Survey (KiKS) instrument consists of 28 items and aims to assess specific knowledge about chronic kidney disease in non-dialysis patients. One point is considered for each correct answer and zero for the incorrect one. The total score is calculated by adding all the correct points and divided by 28, obtaining a value from 0 to 1, with 1 being the highest level of knowledge.
From baseline to week 12
Change in fat free body mass
Time Frame: From baseline to week 12
Fat free body mass in kg assessed by bioelectrical impedance analysis
From baseline to week 12
Change in upper arm circumference
Time Frame: From baseline to week 12
circumference in cm
From baseline to week 12
Change in arm muscle circumference
Time Frame: From baseline to week 12
circumference in cm
From baseline to week 12
waist circumference
Time Frame: From baseline to week 12
circumference in cm
From baseline to week 12
Change in serum potassium concentration (assess kidney function)
Time Frame: From baseline to week 12
serum potassium in mEq/l
From baseline to week 12
Change in serum phosphorus concentration (assess kidney function)
Time Frame: From baseline to week 12
serum phosphorus mg/dl
From baseline to week 12
Change in glomerular filtration (assess kidney function)
Time Frame: From baseline to week 12
Calculated with the formula of CKD-EPI and MDRD and measured in ml/ min/ 1.73 m2
From baseline to week 12
Change in serum albumin concentration
Time Frame: From baseline to week 12
Serum albumin in g/dl
From baseline to week 12
Change in serum prealbumin concentration
Time Frame: From baseline to week 12
Serum prealbumin in mg/dl
From baseline to week 12
Change in TG concentration
Time Frame: From baseline to week 12
Serum TG in mg/dl
From baseline to week 12
Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)
Time Frame: From baseline to week 12
Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl
From baseline to week 12
Changes in blood cells
Time Frame: From baseline to week 12
Blood count
From baseline to week 12
Change in iron concentration
Time Frame: From baseline to week 12
Serum iron in μg/dl
From baseline to week 12
Change in ferritin concentration
Time Frame: From baseline to week 12
Serum ferritin in ng/ml
From baseline to week 12
Change in uric acid concentration
Time Frame: From baseline to week 12
Serum uric acid in mg/dl
From baseline to week 12
Change in urea concentration
Time Frame: From baseline to week 12
Serum uric acid in mg/dl
From baseline to week 12
Change in magnesium concentration
Time Frame: From baseline to week 12
Serum magnesium in mg/dl
From baseline to week 12
Change in calcium concentration
Time Frame: From baseline to week 12
Serum calcium in mg/dl
From baseline to week 12
Change in intact parathyroid hormone (PTHi) concentration
Time Frame: From baseline to week 12
Serum intact parathyroid hormone (PTHi) in pg/ml
From baseline to week 12
Changes in vitamin D
Time Frame: From baseline to week 12
Serum vitamin D in ng/ml
From baseline to week 12
Changes in metabolic control
Time Frame: From baseline to week 12
Measured as HbA1c (glycated hemoglobin)
From baseline to week 12
Assess changes in the degree of depression and / or anxiety
Time Frame: From baseline to week 12
HADS depression and anxiety symptoms screening test. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, the patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11). The score is referred to the last week.
From baseline to week 12
Assess the clinical response after the intervention on functional capacity
Time Frame: From baseline to week 12
Scale of autonomy for activities of daily life "Barthel test". This test measures the capacity of the person to carry out ten basic activities of daily life, obtaining a quantitative estimate of the degree of dependence of the subject. The range of possible IB values is between 0 and 100, with 5-point intervals for the original version. The closer a subject's score is to 0, the more dependency they have; the closer to 100 the more independence.
From baseline to week 12
Assess on functional capacity
Time Frame: From baseline to week 12
Physical activity test "Short Physical Performance Battery" SPPB. This in turn includes 3 tests: balance, gait speed and getting up and sitting in a chair 5 times. Each test is scored from 0 (worst performance) to 4 (best performance): for the balance test according to a hierarchical combination of performance in the 3 component subtests and for the other 2 tests a score of 0 is assigned to those who do not complete or they attempt the task and scores from 1 to 4 based on the time spent. In addition, a total score for the entire battery is obtained, which is the sum of the 3 tests and ranges from 0 to 12.
From baseline to week 12
Changes on functional capacity: International Physical Activity Questionnaire (IPAQ)
Time Frame: From baseline to week 12
The International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. The survey consists of 27 questions and 5 parts.
From baseline to week 12
Change from Handgrip Strength
Time Frame: From baseline to week 12
Strength will be recorded by Jamar Hydraulic Hand Dynamometer (Kg)
From baseline to week 12
Change in handgrip strength
Time Frame: From baseline to week 12
Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.
From baseline to week 12
Changes the clinical response after the intervention in blood pressure figures (mmHg).
Time Frame: From baseline to week 12
Assess if syastolic and diastolic pressure improves after training and at 6 months of follow-up.
From baseline to week 12
Diet composition: PREDIMED test (Prevention with Mediterranean Diet)
Time Frame: From baseline to week 12
Adherence to the Predimed Plus diet pattern 17 (0 - minimum adherence, 17 - maximum adherence)
From baseline to week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gabriel Olveira, MD, PhD, Hospital Regional Universitario de Málaga - FIMABIS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2021

Primary Completion (Actual)

September 30, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

April 8, 2021

First Submitted That Met QC Criteria

September 28, 2021

First Posted (Actual)

October 11, 2021

Study Record Updates

Last Update Posted (Actual)

July 20, 2023

Last Update Submitted That Met QC Criteria

July 19, 2023

Last Verified

February 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Diseases

Clinical Trials on Specific dietary treatment and follow-up using coaching techniques

Subscribe